Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
- Resource Type
- Authors
- Rakha, Emad A; Miligy, Islam M; Quinn, Cecily M; Provenzano, Elena; Shaaban, Abeer M; Marchiò, Caterina; Toss, Michael S; Gallagy, Grace; Murray, Ciara; Walshe, Janice; Katayama, Ayaka; Eldib, Karim; Badr, Nahla; Tanchel, Bruce; Millican-Slater, Rebecca; Purdie, Colin; Purnell, Dave; Pinder, Sarah E; Ellis, Ian O; Lee, Andrew HS
- Source
- Subject
- Receptor, ErbB-2
Gene Amplification
Gene Dosage
Breast Neoplasms
Immunohistochemistry
Neoadjuvant Therapy
Cohort Studies
Case-Control Studies
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Humans
Female
Neoplasm Grading
skin and connective tissue diseases
neoplasms
In Situ Hybridization, Fluorescence
Retrospective Studies
- Language
BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number